Find clinical trials in your area

Search by disease and location to discover available clinical trials matching your criteria.

Matched clinical trials

  • Study of ARI-0001 Cells for Children and Adolescents with Resistant or Refractory Acute Lymphoblastic Leukemia

    Not recruiting

    1 1 1
    Spain
  • Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

    Not recruiting

    1 1 1
    Austria France Germany Italy Spain
  • Study on Nivolumab and Tisagenlecleucel for Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia After Treatment Loss

    Not recruiting

    1 1 1
    Investigated diseases:
    France
  • Study on Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

    Not recruiting

    1 1 1
    Italy
  • Study on Obinutuzumab and Rituximab with Chemotherapy for Adults with Newly Diagnosed CD20-Positive Acute Lymphoblastic Leukemia

    Not recruiting

    1 1 1
    Investigated drugs:
    Poland
  • Study of Venetoclax and Blinatumomab for Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany
  • Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

    Not recruiting

    1 1 1 1
    Austria Czechia Germany Italy Slovakia
  • Study on the Safety and Effectiveness of AUTO1 for Adults with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Using a Drug Combination

    Not recruiting

    1 1 1
    Spain
  • Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Not recruiting

    1 1 1 1
    Austria Belgium Czechia Denmark Finland France +6
  • Study on Acute Lymphoblastic Leukemia Treatment in Children and Adolescents Using Bortezomib, Blinatumomab, and Methotrexate Combination

    Not recruiting

    1 1 1 1
    Poland